Midodrine
Based on 1 Customer Validation
Midodrine is a selective and orally active adrenergic α1-receptor agonist. Midodrine can strengthen vascular contraction. Midodrine can be used for the researches of cardiovascular disease, such as orthostatic hypotension.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.67%
- CAS. Nr.: 42794-76-3
- Formel: C12H18N2O4
- Molecular Weight:254.28
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
α adrenergic receptor |
Midodrine (30 μM, 0-24 h) increases p-AMPK and PPARδ expression in C2C12, HL1 and HepG2 cells[3].
Midodrine (30 μM, 0-1 min) increases Ca2+ in C2C12, HL1 and HepG2 cells[3].
Midodrine (30 μM) increases maximal mitochondrial oxidative phosphorylation and ATP content in C2C12 cells[3].
Midodrine (30-100 μM) reduces cellular lipid content in 3T3-L1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C2C12, HL1 and HepG2 cells
-
Concentration:30 μM
-
Incubation Time:0, 0.5, 1, 3, 6, and 24 h
-
Result:Increased p-AMPK and PPARδ expression.
Midodrine (5 mg/kg, i.g.) shows anti-hypotensive effects in orthostatic hypotension rats models[2].
Midodrine (0.3 mg/kg, p.o., 4 weeks.) relieves hypertension in spontaneously hypertensive rats models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Orthostatic hypotension rats models[2]
-
Dosage:5 mg/kg
-
Administration:Orally gavage
-
Result:Remarkably increased the baselines of SBP, DBP and MAP, but decreased HR.
-
Animal Model:Spontaneously hypertensive rats models[3]
-
Dosage:0.3 mg/kg
-
Administration:Orally administration, 4 weeks
-
Result:Increased p-AMPK, PPARδ and PGC-1α expression.
Increased SDH activity and ATP levels.
Increased expression of uncoupling protein 3 (UCP3).
Decreased left ventricular mass and the harvested cardiac weight.
Reduced both systolic and diastolic BP after 1 week.
Reduced serum total cholesterol, LDL cholesterol, and HDL cholesterol.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 42794-76-3
-
Appearance Solid
-
Molecular Weight 254.28
-
Formel C12H18N2O4
-
Color White to off-white
-
SMILES
O=C(NCC(C1=CC(OC)=CC=C1OC)O)CN
-
Synonyms
(±)-Midodrin
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
DMSO : 250 mg/mL (983.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Criscuoli M, et al. Catecholamines released from the adrenal medulla exert a compensatory, protective effect at beta 2-adrenoceptors against Paf-induced death in mice. Br J Pharmacol. 1988 Jan;93(1):132-8. [Content Brief]
[2]. Inchan A, et al. Anti-hypotensive effect of "Yahom Navakot" in rats with orthostatic hypotension. J Tradit Complement Med. 2021 Aug 3;12(2):180-189. [Content Brief]
[3]. Lee YJ, et al. Stimulation of Alpha1-Adrenergic Receptor Ameliorates Cellular Functions of Multiorgans beyond Vasomotion through PPARδ. PPAR Res. 2020 Feb 1;2020:3785137. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9327 mL | 19.6634 mL | 39.3267 mL | 98.3168 mL |
| 5 mM | 0.7865 mL | 3.9327 mL | 7.8653 mL | 19.6634 mL | |
| 10 mM | 0.3933 mL | 1.9663 mL | 3.9327 mL | 9.8317 mL | |
| 15 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL | 6.5545 mL | |
| 20 mM | 0.1966 mL | 0.9832 mL | 1.9663 mL | 4.9158 mL | |
| 25 mM | 0.1573 mL | 0.7865 mL | 1.5731 mL | 3.9327 mL | |
| 30 mM | 0.1311 mL | 0.6554 mL | 1.3109 mL | 3.2772 mL | |
| 40 mM | 0.0983 mL | 0.4916 mL | 0.9832 mL | 2.4579 mL | |
| 50 mM | 0.0787 mL | 0.3933 mL | 0.7865 mL | 1.9663 mL | |
| 60 mM | 0.0655 mL | 0.3277 mL | 0.6554 mL | 1.6386 mL | |
| 80 mM | 0.0492 mL | 0.2458 mL | 0.4916 mL | 1.2290 mL | |
| 100 mM | 0.0393 mL | 0.1966 mL | 0.3933 mL | 0.9832 mL |